Претрага




Резултати

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)   [2013]

Younes, Anas; ...; Todorovic, Marija; ...; (broj, koautora 16)

HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j   [2021]

Laeufle, Rita; ...; Andric, Zoran G  ; ...; Nikolic, Ivan V  ; ...; Radosavljevic, Davorin Z; ...; (broj, koautora 16)

EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.   [2022]

Weichenthal, Michael; ...; Kandolf-Sekulovic, Lidija O; ...; (broj, koautora 20)

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC   [2013]

Stupp, Roger; ...; Grujicic, Danica M; ...; (broj, koautora 20)

The differences in rate and duration of complete remission between HER2-positive and HER2-negative inflammatory breast carcinoma   [2009]

Kolarevic, Daniela; Tomasevic, Zorica I  ; Andjelic-Dekic, Natasa; Milosevic, Snezana; Jelic, Svetislav B

A phase IIa study of light-activated talaporfin sodium in patients with primary or recurrent glioblastoma multiforme   [2009]

Keltner, L; Chen, JC; Wang, S; Rakic, Miodrag L

Preoperative radiation (Preop RT) in rectal cancer additional chemotherapy - effect and timing of (CT) 5-year results of the EORTC 22921 trial   [2005]

Bosset, J. F.; Calais, G.; Mineur, L.; Maingon, P.; Radošević-Jelić, Ljiljana ; Daban, A.; Bardet, D. E.; Beny, A.; Ollier, J. C.; Collette, L.

Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)   [2011]

Nikolić, Vladimir  ; Ciuleanu T; Shacham E; Vrbanec D; Plate S; Mrsic Z; Kahan Z; Purkalne G; Brodowicz T; Zielinski C

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer   [2024]

Spigel, David R; ...; Stojanovic, Goran; ...; Andric, Zoran G  ; ...; (broj, koautora 17)

Characteristics of HER2 3+ metastatic breast cancer patients with long-term benefit of trastuzumab.   [2017]

Tomašević, Zorica I.  ; Tomašević, Zoran ; Minić, Ivana  ; Kolarević, Daniela 

Филтери

По типу